Skip to main content
Premium Trial:

Request an Annual Quote

Skyline, Ribeirao Preto Medical School Collaborate on AML Study

NEW YORK (GenomeWeb) – SkylineDx and the Ribeirão Preto Medical School at the University of São Paulo on Tuesday said they have begun collaborating on a study using SkylineDx's AMLprofiler test on acute myeloid leukemia patients.

The study is expected to last five years, during which 500 patient samples will be collected throughout South America. The aim of the project is to improve the diagnosis of AML and determine the feasibility of autologous stem cell transplantation as consolidation treatment for patients with low to intermediate risk of the disease. The research will be conducted in the laboratory of Eduardo Magalhães Rego, a professor at Ribeirão Preto Medical School, whose work focuses on the molecular basis of acute leukemia, and the diagnosis, treatment, and monitoring of the disease.

AMLprofiler determines relevant diagnostic and prognostic biomarkers with one single microarray-based assay, SkylineDx said, adding it provides faster results, as well as improved patient classification.

SkylineDx is based in Rotterdam, Netherlands and develops diagnostic tests based on genetic biomarkers.